Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ayu Kiritani"'
Autor:
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 10, Pp 788-796 (2024)
Abstract Background It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely genet
Externí odkaz:
https://doaj.org/article/93acc07c0f8341ceb4a0c0b39dc0fe16
Autor:
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 402-409 (2024)
Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertin
Externí odkaz:
https://doaj.org/article/bf9f4e65fe294138b6c32c0d9d62d1af
Autor:
Yoshiaki Amino, Siew‐Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3317-3322 (2023)
Abstract Background KRAS mutation positive lung cancer is known to be clinically characterized by older age, males, and smokers. It is reported to be more common in mucinous adenocarcinoma, but all reports are based on analysis of tissue samples. Rec
Externí odkaz:
https://doaj.org/article/65050a39348140f4a87a937f35d99782
Autor:
Ryo Ariyasu, MD, Sho Kakuto, MD, Keiki Miyadera, MD, Takahiro Akita, MD, Ayu Kiritani, MD, Ryosuke Tsugitomi, MD, Yoshiaki Amino, MD, Ken Uchibori, MD, PhD, Satoru Kitazono, MD, PhD, Noriko Yanagitani, MD, PhD, Makoto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100524- (2023)
Introduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the re
Externí odkaz:
https://doaj.org/article/461d74d1b3d4494e8199e62cc0a7c7d3
Autor:
Siew-Kee, Low, Ryo, Ariyasu, Ken, Uchibori, Rie, Hayashi, Hiu Ting, Chan, Yoon Ming, Chin, Takahiro, Akita, Yuhei, Harutani, Ayu, Kiritani, Ryosuke, Tsugitomi, Ryo, Manabe, Shinsuke, Ogusu, Yoshiaki, Amino, Satoru, Kitazono, Noriko, Yanagitani, Yusuke, Nakamura, Makoto, Nishio
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Genomic profiling of tumors from cancer patients facilitates molecular-guided therapy. The turnaround time is one of important issues to deliver results timely for clinical decisions. The Ion Torrent™ Genexus™ Integrated Sequencer aut
Autor:
Shinsuke Ogusu, Ryo Ariyasu, Takahiro Akita, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Investigational new drugs. 40(6)
Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non-small cell lung cancer (NSCLC) is limited. EGFR-TKI re-administration efficacy ma
Autor:
Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Takahiro Akita, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
JTO Clinical and Research Reports. :100524
Autor:
Kazuyoshi Kuwano, Daisuke Takekoshi, Hirohumi Utsumi, Yoshinori Kawabata, Hiromichi Hara, Mitsuo Hashimoto, Jun Araya, Rei Makishima, Hiroshi Wakui, Masahiro Ikegami, Hanae Miyagawa, Takuya Akutsu, Junko Watanabe, Ayako Nishioka, Yuma Matsui, Yuki Noda, Takanori Numata, Shunsuke Minagawa, Ayu Kiritani, Keitaro Okuda
Publikováno v:
Internal Medicine
We report the case of a 56-year-old man with chronic myeloid leukemia (CML) who developed dasatinib-induced interstitial lung disease (ILD) 7 years after starting dasatinib, a BCR-ABL1 inhibitor. The patient presented with dyspnea. Chest imaging show
Autor:
Yumie Yamanaka, Ayu Kiritani, Chiaki Hosoda, Yoshitaka Seki, Kazuyoshi Kuwano, Naoaki Watanabe, Shota Fujimoto, Keisuke Saito, Ikumi Fujisaki, Hiroshi Takeda, Yasuhiko Endo, Akira Kinoshita, Hanae Miyagawa
Publikováno v:
Journal of Infection and Chemotherapy. 26:274-278
Invasive pulmonary aspergillosis (IPA) patients with non-hematological malignancy are far less than with hematological malignancy patients. We encountered a very rare case of IPA in which type 1 diabetes was the only conceivable risk factor. Further,
Autor:
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Annals of Oncology. 33:S510-S511